Vivanza Biosciences

Ahmedabad, India Founded: 1982 • Age: 44 yrs Listed
Pharmaceutical products and medical gloves are manufactured in India.
Request Access
Report Incorrect Data
Page last updated

About Vivanza Biosciences

Vivanza Biosciences is a publicly listed company based in Ahmedabad (India) founded in 1982. Pharmaceutical products and medical gloves are manufactured in India. It operates on a HealthTech and Reseller / Distribution model. Its Indian entity Vivanza Biosciences Limited reported revenue of ₹116 Cr. Vivanza Biosciences offers products and services including Latex Examination Gloves, Remdesivir for Injection, and Nitrile Examination Gloves. Its focus areas include Pharmaceuticals and Drug Manufacturing.

Company details

Vivanza Biosciences Limited is involved in the manufacturing and marketing of pharmaceutical products, with a focus on biosciences. The company operates in the healthcare sector, offering a range of medical gloves and injectable products like Remdesivir. Solutions are provided for medical practitioners and patients globally, supported by experienced professionals and technocrats. Collaboration with global partners is emphasized to enhance decision-making and service delivery.

  • Headquarters Ahmedabad, India
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website vivanzabiosciences.com
  • Social X Facebook Instagram
  • Legal Name Vivanza Biosciences Ltd.
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹5.84 Cr

    VIVANZA · BSE

  • Share Price
    ₹1.40

    -4.11% today

  • Revenue
    ₹116 Cr

    FY 2025-26 · +1462.1% YoY

  • EBITDA
    ₹0.74 Cr

    Margin 0.6%

  • Net Profit
    ₹0.40 Cr

    FY 2025-26 · +158.8% YoY

  • P/E (TTM)
    13.6x

    P/B 1.4x

  • ROE
    9.4%

    ROCE 6.0%

  • Debt / Equity
    2.26

    Interest cover 38.9x

Products & Services of Vivanza Biosciences

Vivanza Biosciences offers a comprehensive portfolio of products and services, including Latex Examination Gloves, Remdesivir for Injection, and Nitrile Examination Gloves.

Latex Examination Gloves
Medical Gloves

Gloves are provided for medical examination purposes.

Remdesivir for Injection
Injectable Products

Injectable solution is offered for medical treatment needs.

Nitrile Examination Gloves
Medical Gloves

Latex-free gloves are supplied for medical examinations.

Board of directors of Vivanza Biosciences Limited (Vivanza Biosciences)

Vivanza Biosciences Limited is the primary company behind Vivanza Biosciences. The board of Vivanza Biosciences Limited currently have 4 directors; the longest-serving is Jayendra Mehta, appointed in 2023. 24 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Jayendra Mehta
DIN 08210602
Managing Director25 Apr 20233 yrs 6 moVivanza Biosciences Limited
Rina Kumari
DIN 10588570
Director30 Apr 20242 yrs 6 moVivanza Biosciences Limited
Hitesh Pradeep Rijwani
DIN 11030634
Director12 May 20251 yr 5 moVivanza Biosciences Limited
Sarang Bharat Pathak
DIN 02663344
Director30 Aug 20251 yr 2 moVivanza Biosciences Limited

People of Vivanza Biosciences

1 people are tracked at Vivanza Biosciences (1 in leadership).

NameRoleGroup
Bhaskar Bhattacharya
Managing DirectorLeadership
Premium access

Complete people profiles for Vivanza Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Vivanza Biosciences

Vivanza Biosciences is a publicly listed company on the BSE with ticker symbol VIVANZA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date24 Mar 2003
  • Listed onBSE: 530057
  • Listed entityVivanza Biosciences Ltd.
  • Exchange sectorHealth technology
  • ISININE984E01035
  • Share price₹1.67 · 2026-10-14
  • Market capitalisation₹6.7 Cr
  • Price to earnings14.7
  • EPS (diluted, trailing year)₹0.11
  • Volume (last session)6,163

Financials of Vivanza Biosciences

Exchange-reported figures of Vivanza Biosciences Limited, the listed company behind Vivanza Biosciences (BSE: VIVANZA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹116 Cr
+1462.1% YoY
EBITDA
₹0.74 Cr
+300.0% YoY
Profit After Tax
₹0.40 Cr
+158.8% YoY
Net Worth
₹4.36 Cr
+10.1% YoY
Total Assets
₹14.55 Cr
+15.3% YoY
Total Debt
₹10.19 Cr
+17.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1167.4227.8417.8110.409.899.62
Revenue growth+1462.1%-73.4%+56.3%+71.3%+5.2%+2.8%-
EBITDA0.74(0.37)1.080.68(0.07)0.11(0.35)
EBITDA margin+0.6%-5.0%+3.9%+3.8%-0.7%+1.1%-3.6%
Profit before tax0.55(0.67)0.700.730.320.14(0.22)
Net profit0.40(0.68)0.550.610.320.09(0.22)
Net profit margin+0.4%-9.2%+2.0%+3.4%+3.1%+0.9%-2.3%
EPS (₹)0.10(0.17)0.140.150.830.19(0.51)
Balance sheet
Total assets14.5512.629.8112.099.003.523.47
Net worth4.363.964.644.093.493.163.08
Total debt10.198.655.178.005.510.360.39
Cash & bank0.070.120.170.140.06(3.09)(2.78)
Net working capital11.538.556.059.165.900.080.25
Cash flow
Cash from operations(2.58)(2.50)2.04(0.95)2.47(3.08)2.98
Cash from investing(0.12)(0.01)(0.04)0.000.00(0.02)0.00
Cash from financing2.652.46(1.98)1.03(2.48)2.80(2.75)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9.296.3645.2555.368.940.481.503.00
Revenue growth (YoY)+3.9%+1225.0%+2916.7%+1745.3%+266.4%---
Other income0.370.010.080.010.020.050.010.00
EBITDA(0.08)(0.24)0.210.610.15(0.96)0.120.11
EBITDA margin-0.9%-3.8%+0.5%+1.1%+1.7%-200.0%+8.0%+3.7%
Depreciation0.010.010.000.000.000.000.000.00
Interest0.110.070.090.050.080.080.090.09
Profit before tax0.17(0.31)0.200.570.09(0.99)0.040.02
Tax0.040.150.000.000.000.010.000.00
Net profit0.13(0.46)0.200.570.09(1.00)0.040.02
EPS (₹)0.04(0.11)0.050.140.02(0.25)0.010.00
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1122.9414.4114.219.159.229.43
Revenue growth+3717.4%-79.6%+1.4%+55.3%-0.8%-2.2%-
EBITDA0.71(0.38)0.800.730.080.12(0.31)
EBITDA margin+0.6%-12.9%+5.6%+5.1%+0.9%+1.3%-3.3%
Profit before tax0.52(0.71)0.420.690.470.14(0.22)
Net profit0.38(0.71)0.310.570.470.09(0.22)
Net profit margin+0.3%-24.2%+2.2%+4.0%+5.1%+1.0%-2.3%
EPS (₹)0.09(0.17)0.080.141.160.25(0.51)
Balance sheet
Total assets11.8910.117.9810.968.253.543.44
Net worth4.404.024.724.403.833.373.27
Total debt7.506.093.266.564.420.180.18
Cash & bank0.020.050.090.100.02(3.11)(2.81)
Net working capital9.277.595.448.445.741.030.94
Cash flow
Cash from operations(1.21)(2.47)1.800.16(0.68)(3.08)2.80
Cash from investing(0.12)(0.01)(0.04)0.000.00(0.02)0.00
Cash from financing1.312.44(1.77)(0.08)0.652.80(2.58)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9.145.7544.9353.737.820.170.761.58
Revenue growth (YoY)+16.9%+3282.4%+5811.8%+3300.6%+1718.6%---
Other income0.370.010.080.010.020.020.010.00
Total expenses9.225.8044.7653.237.741.070.641.48
EBITDA(0.08)(0.05)0.170.500.08(0.90)0.120.10
EBITDA margin-0.9%-0.9%+0.4%+0.9%+1.0%-529.4%+15.8%+6.3%
Depreciation0.010.010.000.000.000.000.000.00
Interest0.110.070.090.050.080.080.090.09
Profit before tax0.17(0.12)0.160.460.02(0.96)0.040.01
Tax0.040.140.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 03 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9.296.3645.2555.368.940.481.503.00
Revenue growth (YoY)+3.9%+1225.0%+2916.7%+1745.3%+266.4%---
Other income0.370.010.080.010.020.050.010.00
EBITDA(0.08)(0.24)0.210.610.15(0.96)0.120.11
EBITDA margin-0.9%-3.8%+0.5%+1.1%+1.7%-200.0%+8.0%+3.7%
Depreciation0.010.010.000.000.000.000.000.00
Interest0.110.070.090.050.080.080.090.09
Profit before tax0.17(0.31)0.200.570.09(0.99)0.040.02
Tax0.040.150.000.000.000.010.000.00
Net profit0.13(0.46)0.200.570.09(1.00)0.040.02
EPS (₹)0.04(0.11)0.050.140.02(0.25)0.010.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1167.4227.8417.8110.409.899.62
Revenue growth+1462.1%-73.4%+56.3%+71.3%+5.2%+2.8%-
Other income0.110.060.050.480.830.510.57
Total expenses1157.7926.7617.1310.479.789.97
Employee cost0.490.580.450.310.250.340.30
EBITDA0.74(0.37)1.080.68(0.07)0.11(0.35)
EBITDA margin+0.6%-5.0%+3.9%+3.8%-0.7%+1.1%-3.6%
Depreciation0.020.010.010.000.010.010.00
Interest0.280.350.420.430.430.470.44
Profit before tax0.55(0.67)0.700.730.320.14(0.22)
Tax0.150.010.150.120.000.050.00
Net profit0.40(0.68)0.550.610.320.09(0.22)
Net profit margin+0.4%-9.2%+2.0%+3.4%+3.1%+0.9%-2.3%
EPS (₹)0.10(0.17)0.140.150.830.19(0.51)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital4.004.004.004.004.004.004.00
Reserves & surplus0.36(0.04)0.640.09(0.51)(0.84)(0.92)
Shareholders' funds (net worth)4.363.964.644.093.493.163.08
Minority interest0.000.000.000.000.000.000.00
Secured loans0.100.000.000.000.000.000.00
Unsecured loans10.098.655.178.005.510.360.39
Total debt10.198.655.178.005.510.360.39
Total liabilities14.5512.629.8112.099.003.523.47
Assets
Gross block2.692.572.562.522.522.522.50
Net block2.442.342.342.312.322.322.31
Capital work in progress0.000.000.000.000.000.000.00
Investments0.000.000.000.000.000.000.00
Inventories3.552.262.012.472.430.650.97
Sundry debtors12.388.0611.5412.487.846.256.54
Cash & bank balances0.070.120.170.140.06(3.09)(2.78)
Loans & advances3.061.952.034.462.131.204.41
Total current assets19.0612.3915.7519.5512.465.019.14
Total current liabilities7.533.849.7010.396.564.938.89
Net working capital11.538.556.059.165.900.080.25
Total assets14.5512.629.8112.099.003.523.47
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.120.170.140.060.07(2.81)(3.00)
Net cash from operating activities(2.58)(2.50)2.04(0.95)2.47(3.08)2.98
Net cash from investing activities(0.12)(0.01)(0.04)0.000.00(0.02)0.00
Net cash from financing activities2.652.46(1.98)1.03(2.48)2.80(2.75)
Net change in cash(0.05)(0.05)0.030.09(0.01)(0.30)0.22
Closing cash0.070.120.170.140.06(3.09)(2.78)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1462.1%-73.4%+56.3%+71.3%+5.2%+2.8%-
EBITDA growth+300.0%-134.3%+58.8%+1071.4%-163.6%+131.4%-
PBT growth+9998.0%--4.1%+128.1%+128.6%+9998.0%+48.8%
Net income growth+158.8%-223.6%-9.8%+90.6%+255.6%+140.9%-
Revenue CAGR (3Y)+86.7%-10.6%+41.2%+22.8%+57.5%+15.4%+40.5%
EBITDA CAGR (3Y)+2.9%+74.2%+114.1%-+91.3%-43.5%+3.0%
Profitability & leverage
Net income margin+0.4%-9.2%+2.0%+3.4%+3.1%+0.9%-2.3%
Return on capital employed+6.0%0.0%+10.2%+10.7%+11.0%+15.3%0.0%
Return on net worth+9.4%0.0%+12.6%+14.8%+8.3%+2.3%0.0%
Debt / equity2.261.611.511.780.880.120.29
Long-term debt / equity0.510.700.470.530.390.030.12
Interest cover38.89-92.1139.2563.24-537.50470.00-125.71
Efficiency & per share
Fixed asset turnover44.072.8910.967.074.133.943.85
Inventory turnover39.903.4812.437.276.7512.216.48
Debtors turnover11.340.762.321.751.481.551.57
EPS (₹)0.10(0.17)0.140.150.830.19(0.51)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)1.090.991.161.028.737.907.71
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9.145.7544.9353.737.820.170.761.58
Revenue growth (YoY)+16.9%+3282.4%+5811.8%+3300.6%+1718.6%---
Other income0.370.010.080.010.020.020.010.00
Total expenses9.225.8044.7653.237.741.070.641.48
EBITDA(0.08)(0.05)0.170.500.08(0.90)0.120.10
EBITDA margin-0.9%-0.9%+0.4%+0.9%+1.0%-529.4%+15.8%+6.3%
Depreciation0.010.010.000.000.000.000.000.00
Interest0.110.070.090.050.080.080.090.09
Profit before tax0.17(0.12)0.160.460.02(0.96)0.040.01
Tax0.040.140.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1122.9414.4114.219.159.229.43
Revenue growth+3717.4%-79.6%+1.4%+55.3%-0.8%-2.2%-
Other income0.110.030.050.390.830.500.53
Total expenses1123.3213.6113.489.079.109.74
Employee cost0.330.370.310.220.080.110.10
EBITDA0.71(0.38)0.800.730.080.12(0.31)
EBITDA margin+0.6%-12.9%+5.6%+5.1%+0.9%+1.3%-3.3%
Depreciation0.020.010.010.000.010.010.00
Interest0.280.350.420.430.430.470.44
Profit before tax0.52(0.71)0.420.690.470.14(0.22)
Tax0.140.000.110.120.000.050.00
Net profit0.38(0.71)0.310.570.470.09(0.22)
Net profit margin+0.3%-24.2%+2.2%+4.0%+5.1%+1.0%-2.3%
EPS (₹)0.09(0.17)0.080.141.160.25(0.51)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital4.004.004.004.004.004.004.00
Reserves & surplus0.400.020.720.40(0.17)(0.63)(0.73)
Shareholders' funds (net worth)4.404.024.724.403.833.373.27
Secured loans0.100.000.000.000.000.000.00
Unsecured loans7.406.093.266.564.420.180.18
Total debt7.506.093.266.564.420.180.18
Total liabilities11.8910.117.9810.968.253.543.44
Assets
Gross block0.190.070.060.020.020.020.00
Net block0.120.020.030.000.000.010.00
Capital work in progress0.000.000.000.000.000.000.00
Investments1.911.911.911.911.911.911.91
Inventories2.951.841.801.612.230.400.85
Sundry debtors10.667.3910.3712.187.356.116.41
Cash & bank balances0.020.050.090.100.02(3.11)(2.81)
Loans & advances1.972.112.084.032.102.025.32
Total current assets15.6011.3914.3417.9211.705.429.77
Total current liabilities6.333.808.909.485.964.398.83
Net working capital9.277.595.448.445.741.030.94
Total assets11.8910.117.9810.968.253.543.44
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.050.090.100.020.05(2.81)(3.03)
Net cash from operating activities(1.21)(2.47)1.800.16(0.68)(3.08)2.80
Net cash from investing activities(0.12)(0.01)(0.04)0.000.00(0.02)0.00
Net cash from financing activities1.312.44(1.77)(0.08)0.652.80(2.58)
Net change in cash(0.03)(0.04)(0.01)0.09(0.03)(0.30)0.22
Closing cash0.020.050.090.100.02(3.11)(2.81)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3717.4%-79.6%+1.4%+55.3%-0.8%-2.2%-
EBITDA growth+286.8%-147.5%+9.6%+812.5%-33.3%+138.7%-
PBT growth+9998.0%--39.1%+46.8%+235.7%+9998.0%+51.1%
Net income growth+153.5%-329.0%-45.6%+21.3%+422.2%+140.9%-
Revenue CAGR (3Y)+99.2%-31.5%+16.1%+14.7%+60.3%+12.7%+39.6%
EBITDA CAGR (3Y)-0.9%-+88.2%---42.8%+24.7%
Profitability & leverage
Net income margin+0.3%-24.2%+2.2%+4.0%+5.1%+1.0%-2.3%
Return on capital employed+7.3%-3.9%+9.0%+11.6%+14.1%+16.3%0.0%
Return on net worth+9.0%-16.0%+7.0%+13.6%+11.5%+2.8%0.0%
Debt / equity1.611.071.081.330.640.050.16
Long-term debt / equity0.200.180.080.000.000.000.00
Interest cover40.58-89.7453.1658.90614.29427.27-141.94
Efficiency & per share
Fixed asset turnover863.3145.23360.25710.50457.50922.000.00
Inventory turnover46.861.628.457.406.9614.756.83
Debtors turnover12.440.331.281.461.361.471.58
EPS (₹)0.09(0.17)0.080.141.160.25(0.51)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)1.101.011.181.109.578.418.16

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Vivanza Biosciences (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vivanza Biosciences

Vivanza Biosciences consolidated net profit rises 66.67% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
Vivanza Biosciences consolidated net profit declines 34.62% in the September 2022 quarter
India Infoline • 1 year ago
Vivanza Biosciences to table results
India Infoline • 1 year ago
Vivanza Biosciences Approves Borrowing To Be Increased To 200 Million Rupees
Reuters • 3 years ago
Vivanza Biosciences Names Jayendra Mehta As Managing Director
Reuters • 3 years ago
Pharma stock sets record date for 1:10 stock split, net income up 281% in Q3
Livemint • 3 years ago
Vivanza Biosciences Approved Sub-Division Of 1 Share Of Co Into 10 Shares
Reuters • 3 years ago
Vivanza Biosciences Is In Receipt Of Work Orders Worth Approx $1 Mln In Institutional And Industrial Categories
Reuters • 3 years ago
Vivanza Biosciences To Consider Sub-Division Of Shares
Reuters • 3 years ago
Vivanza Biosciences Decides To Shelve Preferential Allotment Plan
Reuters • 3 years ago
Premium access

Complete news archive for Vivanza Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vivanza Biosciences

Vivanza Biosciences was founded in 1982.

Vivanza Biosciences is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

The primary company behind Vivanza Biosciences, Vivanza Biosciences Limited, reported revenue of ₹116 Cr for FY 2026, up 1462% year on year.

Vivanza Biosciences Limited is involved in the manufacturing and marketing of pharmaceutical products, with a focus on biosciences. The company operates in the healthcare sector, offering a range of medical gloves and injectable products like Remdesivir. Solutions are provided for medical practitioners and patients globally, supported by experienced professionals and technocrats. Collaboration with global partners is emphasized to enhance decision-making and service delivery.

Vivanza Biosciences offers Latex Examination Gloves, Remdesivir for Injection, and Nitrile Examination Gloves.

Yes, Vivanza Biosciences is publicly traded on BSE under the ticker symbol VIVANZA.

Vivanza Biosciences operates through Vivanza Biosciences Limited.

The legal entities of Vivanza Biosciences currently have 5 directors, including Rina Kumari, Jayendra Mehta, Sarang Bharat Pathak and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available